Azura Ophthalmics is a clinical-stage biotechnology company headquartered in Tel Aviv-Yafo, Israel. Azura Ophthalmics is developing an innovative portfolio of compounds in combination with a novel drug delivery platform to advance a portfolio of treatments for Meibomian gland dysfunction (MGD), the leading cause of dry eye disease.

By targeting the root cause of MGD, Azura Ophthalmics brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and its associated ocular surface diseases for which there are currently no effective pharmaceutical treatments.

Azura Ophthalmics is underpinned by an experienced management team with an established record of successfully developing and launching both novel devices and pharmaceuticals for the treatment of ocular surface diseases